Membranous Nephropathy Pathophysiology and Treatment Approaches

Membranous nephropathy (MN) is an autoimmune glomerular disorder characterised by subepithelial immune complex deposition, complement activation and podocyte injury, leading to heavy proteinuria and nephrotic syndrome. In primary MN, circulating autoantibodies—most often directed against the phospholipase A2 receptor (PLA2R) on podocytes—trigger complement-mediated damage and disruption of the glomerular filtration barrier. Genetic predisposition, autoantibody subclass distribution and environmental factors modulate disease onset and course. Conventional treatments include corticosteroids and cytotoxic agents, while newer strategies focus on B-cell depletion (anti-CD20 therapies) and direct complement inhibition. Advances in molecular and cellular pathology have revealed key pathways in complement activation, podocyte signalling and antibody glycosylation, setting the stage for precision therapies that may improve efficacy and reduce adverse effects.

Research from Nature Portfolio

Recent studies have shown that complement activation in MN occurs predominantly via the classical pathway. Immunohistochemical analyses of patient biopsies reveal co-localisation of C1q with IgG subclasses at sites of immune complex deposition, and murine models with targeted C3 silencing via RNA interference demonstrate marked reductions in proteinuria and preservation of podocyte architecture, identifying C3 as a compelling therapeutic target. A large genome-wide association study across European and East Asian populations has uncovered novel risk loci at NFKB1 and IRF4 and fine-mapped the PLA2R1 locus, collectively explaining up to one-third of disease susceptibility and underscoring the potential of genetic profiling to stratify patients and refine non-invasive diagnostics. An updated meta-analysis of serological anti-PLA2R testing and glomerular PLA2R staining has confirmed high specificity for distinguishing primary from secondary MN, supporting combined serological and histological assessment to guide early treatment decisions.

Membranous Nephropathy Pathophysiology and Treatment Approaches publication trend

The graph below shows the total number of articles in membranous nephropathy pathophysiology and treatment approaches across all publications each year (not limited to Nature Index journals).

Technical terms

Podocyte: Specialized epithelial cell lining glomerular capillaries, crucial for maintaining the kidney’s filtration barrier.

Complement system: A cascade of plasma proteins in innate immunity that, when activated via classical, lectin or alternative pathways, promotes inflammation and cell lysis.

Phospholipase A2 receptor (PLA2R): A transmembrane antigen expressed on podocytes and the principal target of autoantibodies in primary MN.

Genome-wide association study (GWAS): A method that scans the genome to identify genetic variants associated with disease risk.

Proteinuria: Abnormal excretion of protein in urine, a hallmark of glomerular injury and podocyte dysfunction.

References

1. The classical pathway triggers pathogenic complement activation in membranous nephropathy. Nature Communications (2023).
2. Podocyte Pathogenic Bone Morphogenetic Protein‐2 Pathway and Immune Cell Behaviors in Primary Membranous Nephropathy. Advanced Science (2024).
3. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications (2020).
4. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Scientific Reports (2015).
5. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1 associated membranous nephropathy. Journal of Clinical Investigation (2021).